<DOC>
	<DOCNO>NCT03019536</DOCNO>
	<brief_summary>The study involve repeat dos LY3303560 give injection 48 week . The study examine safe repeat dos LY3303560 , whether cause side effect participant mild cognitive impairment Alzheimer 's Disease , LY3303560 handle body act body . This study last 64 week , include screen . Screening require within 70 day prior start study .</brief_summary>
	<brief_title>A Study LY3303560 Participants With Mild Cognitive Impairment Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Mild Cognitive Impairment ( MCI ) due Alzheimer 's Disease ( AD ) mildtomoderate AD base National Institute Aging Alzheimer 's Association diagnostic criterion Female participant : woman childbearing potential may participate , include : Infertile due surgical sterilisation ( hysterectomy , bilateral oophorectomy , country outside Japan , tubal ligation ) , congenital anomaly mullerian agenesis ; Postmenopausal define woman least 50 year age intact uterus take hormone oral contraceptive within 1 year , either cessation menses least 1 year , 6 12 month spontaneous amenorrhea folliclestimulating great ( &gt; ) 40 milliinternational unit per millilitre ( mIU/mL ) Have body weight least 50 kilogram ( kg ) ( except Japanese site ) body mass index ( BMI ) 18.0 35.0 kilogram per meter square ( kg/mÂ² ) ( site ) , inclusive , screen Are currently enrol clinical trial involve investigational product ( IP ) type medical research judge scientifically medically compatible study Have participate , within last 30 day ( 3 month 4 month sit European Union [ EU ] Japan , respectively ) clinical trial involve IP . If previous IP long halflife , 3 month ( 4 month sit Japan ) 5 halflives ( whichever longer ) pass Have know allergy LY3303560 , related compound component formulation , history significant atopy Have significant allergy humanise monoclonal antibody , diphenhydramine , adrenaline , methylprednisolone ; history clinically significant multiple severe drug allergy , intolerance topical corticosteroid , severe post treatment hypersensitivity reaction ( include , limited , erythema multiforme major , linear immunoglobulin A dermatosis , toxic epidermal necrolysis , exfoliative dermatitis ) Have increase risk seizure evidence history head trauma loss consciousness within last 5 year seizure ; prior electroencephalogram epileptiform activity ; surgery cerebral cortex ; history within last 5 year serious infectious disease affect brain Have contraindication Magnetic Resonance Imaging ( MRI ) study , include claustrophobia , presence metal ( ferromagnetic ) implant cardiac pacemaker Have history intracranial haemorrhage , cerebrovascular aneurysm , arteriovenous malformation , carotid artery occlusion , epilepsy Have receive acetylcholinesterase inhibitor ( AChEIs ) , memantine , and/or AD therapy le 4 week , less 4 week stable therapy treatment time randomisation ( include less 4 week since stop AChEIs and/or memantine ) ; receive medication affect central nervous system , except treatment AD , less 4 week stable dose Have use stable medical therapy le 2 month concurrent medical condition exclusionary Are currently use intend use drug know significantly prolong QT interval , know risk factor Torsades de Pointes Show clinically significant abnormality lumbar spine ( Part A ) Have history clinically significant back pain , back pathology and/or back injury may predispose complication technical difficulty lumbar puncture ( Part A ) Have criterion would preclude lumbar puncture ( Part A )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>